Starbucks will cease covering GLP-1 weight-loss drugs for employees starting October. This decision reflects rising costs and a broader employer trend in benefits. GLP-1 drugs, initially for diabetes, are now popular for obesity treatment. Other companies like Allina Health and PwC have also adjusted their coverage policies. However, Bank of America views GLP-1 coverage as a vital employee health investment.